History

1999
The company was established in August 1999 as a spin-off from the Robert-Koch Institute (RKI) in Berlin. Minerva Biolabs GmbH started with innovative products for the effective diagnosis and elimination of mycoplasma contamination in cell cultures and biopharmaceuticals.

2000
The transition to a quality management system (QMS) in accordance with ISO 9001:2000 has been made in November 2000.

2001
Based on our experience with the production of high quality and reliable diagnostics for biopharmaceutical quality control, Minerva Biolabs transferred this know-how to the development of clinical diagnostics for respiratory infections in 2001.

2004
The consequential expansion of our product range led in the beginning of 2004 to the introduction of the worldwide first bacterial diagnostic assay. Another innovative improvement followed the same year by the integration of the Aqua Screen® System into the portfolio of contamination control solutions. The Aqua Screen® System provides a highly efficient method for the filtration and detection of legionella in water. The transition to a quality management system in accordance with ISO 13485:2003 has been made in July 2004.

2005
As a direct result of our steadily expanding product portfolio we are pleased to present our first product catalogue at the beginning of 2005.

2006
Minerva Biolabs develops two new products for the PCR Detection and the control of microbial contaminants. The PCR-Assays Venor®GeM-qEP and Venor®GeM-qDual can be used for the detection of mycoplasma DNA. Both products were launched in the beginning of 2007.

2007
In June Minerva opens its new company building with state of the art laboratories, production facilities and offices on the site of the Vivantes-Wilhelm-Griesinger hospital in Berlin-Marzahn.

2008
In the beginning of the year Minerva Biolabs expands his product range with two new clinical test kits Onar®MRSA and Onar®Tp. Onar®MRSA in vitro test system for quantitative and rapid PCR-based detection of Methicillin-resistant Staphylococcus aureus in clinical samples. Another innovative improvement followed with Mynox®Gold, a further development of the classical Mynox®, which was known for a very high elimination efficiency and low cytotoxicity. Mynox®Gold is a combination of a standard antibiotic and a biological reagent.

2009
Minerva Biolabs developed the PCR Assay Venor®GeM Advance, a further development of the classical Venor®GeM PCR Detection Kit. Another innovative development followed the same year with Zell Shield – The Cell Culture Contamination Preventive, which protects cell cultures from most intracellular and extracellular growing gram negative and gram positive bacteria, mycoplasma, protozoon, fungi and yeast.

2010
Already too small! Minerva accuses back into the Innovationspark Wuhlheide in Berlin Koepenick for a 890 square meter laboratory and office space. The production facility in Marzahn is reduced and is only used for the production of our positive controls.

2011
New drinking water regulations – new orders: Minerva rises in the classic culture method for diagnosis of Legionella. This part as well as the entire diagnostic service have been accreditated in accordance with DIN EN ISO 17025. The mycoplasma diagnostic service also receives the GMP status.